H2O America vs Nuwellis Inc — how do they compare? H2O America trades at $63.79 (market cap $2.70B), while Nuwellis Inc trades at $2.94 (market cap $1.09M). The key difference: H2O America is far larger — about 2477.1× Nuwellis Inc's market cap, and H2O America pays a 2.73% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| HTO | NUWE | |
|---|---|---|
Market Cap | $2.70B | $1.09M |
Sector | Technology | Technology |
52-Week High | $65.43 | $527.46 |
52-Week Low | $44.44 | $2.80 |
Enterprise Value | $4.42B | -$722.58K |
Dividend Yield | 2.73% | — |
Signals from Pluang's Aura AI — not financial advice
HTO trades at $64.52, down 1.39% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported a Q1 2026 EPS beat of $0.50 versus $0.48 expected, with revenue of $816 million in 2026 and a net income margin of 12.86%. A dividend of $0.44 per share is scheduled for payment on June 1, 2026. Analyst consensus is strongly bullish with an 80% buy rating and a $63.50 price target.
The outlook for HTO is positive, supported by steady earnings growth, a reliable dividend, and strong institutional interest. Risks include high capital expenditure demands and sensitivity to regulatory changes in the utilities sector. The stock presents a value opportunity with a P/E of 22.11, trading near analyst targets with potential upside to the high target of $67.00.
No Aura AI signal available yet.
Trailing returns across standard periods
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →